Clinical Trial Update: A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO) [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial updates for duvelisib in combination with rituximab or obinutuzumab in previously untreated CD20+ follicular lymphoma; the study is terminated wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Duvelisib (duvelisib)
• Obinutuzumab (obinutuzumab)
• Rituximab (rituximab)

Snippet

Sponsor: SecuraBio | Conditions: CD20+ Follicular Lymphoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2019-01-08